The Alzheimer’s Association has awarded a $118,673 grant to a researcher at Boston University School of Medicine to study…
Ana de Barros, PhD
Ana holds a PhD in immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. Ana was awarded two FCT fellowships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana de Barros, PhD
A new research study has found that older, cognitively normal adults with elevated levels of cortical amyloid, the protein linked…
AdAlta and Crossbeta Biosciences have entered into a commercialization agreement, granting Crossbeta with a license to three beta-amyloid…
BrightStar Care Offering Q&A Sessions, ‘Connections’ Campaign for Alzheimer’s Awareness Month
BrightStar Care, a national at-home senior care franchise, has launched an Alzheimer’s awareness campaign — Memories and Connections — for…
Roobirk and Antidote, two startup companies that work to empower people living with Alzheimer’s disease have entered a partnership with…
Most National Alzheimer’s Project Studies Not Looking to Show Clinical Benefit, Scientists Argue
Two physicians — one at the University of Pennsylvania’s Perelman School of Medicine and the other with the University of Michigan…
Using laser technology, researchers have found that peptides related to Alzheimer’s Disease move at dangerous speeds prior to clumping or forming…
A recent research study conducted at the University of Eastern Finland has found that psychotropic drug use is more…
Recombinetics has just announced that the National Institute on Aging, part of the National Institutes of Health (NIH), has awarded…
vTv Therapeutics to Detail Potential Alzheimer’s Treatment, Now in Phase 3 Study, at Meeting Today
Larry Altstiel, MD, PhD, chief medical officer of vTv Therapeutics, will speak today on the panel “Novel Approaches to…